Liminal BioSciences
Small molecule therapeutics for metabolic and inflammatory diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | Buyout | |
| Total Funding | 000k | ||
| CAD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 10 % | (81 %) | (32 %) | (81 %) | (38 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (555 %) | (951 %) | (4093 %) | (2587 %) | (7032 %) | (7944 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (492 %) | (793 %) | (4195 %) | (3555 %) | 2003 % | 125 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 419 % | 344 % | 1532 % | 1713 % | 2853 % | 3815 % |
Source: Company filings or news article
Related Content
Liminal BioSciences is a development-stage biopharmaceutical company concentrating on the discovery and creation of novel small molecule therapeutics. The company's primary focus is on modulating G protein-coupled receptor (GPCR) pathways to treat metabolic, inflammatory, and fibrotic diseases with significant unmet medical needs. Liminal's business model is centered on its integrated drug discovery platform, which utilizes medicinal chemistry expertise and a deep understanding of GPCR biology to design and develop proprietary therapeutic candidates.
Originally founded as a commercial spinoff of research from the University of Cambridge in 1988, the company was incorporated in Canada on October 14, 1994, as Innovon Life Sciences Holdings Limited. It has undergone several name changes, becoming Prometic Life Sciences Inc. in 1998 and rebranding to Liminal BioSciences Inc. in October 2019. After trading on the Toronto Stock Exchange and later the Nasdaq, the company was taken private in September 2023 by Thomvest Asset Management Ltd. through its fund, Structured Alpha LP. This followed a strategic decision to divest non-core assets, including its plasma-derived therapeutics business, to streamline operations and focus on its small molecule pipeline.
The company's pipeline includes preclinical and clinical-stage programs. Key candidates have included LMNL6511, a selective antagonist for the GPR84 receptor, and LMNL6326, an antagonist for the OXER1 receptor for eosinophil-driven diseases. By targeting GPCRs—which are the target for approximately 35% of all approved drugs—Liminal aims to capitalize on a significant opportunity for developing new therapeutics, as a large portion of GPCR pathways still lack an approved drug.
Keywords: small molecule therapeutics, GPCR pathways, G protein-coupled receptors, biopharmaceutical, metabolic diseases, inflammatory diseases, fibrotic diseases, drug discovery, medicinal chemistry, clinical-stage, preclinical, Thomvest Asset Management, LMNL6511, GPR84 antagonist, OXER1 antagonist, Prometic Life Sciences